AHA Scientific Sessions 2026 Abstract
Elevated High-Sensitivity C-Reactive Protein as a Prescribing Trigger versus a Risk-Enhancing Factor Identifies Distinct Primary Prevention Populations for Statin Therapy
Cohort study of 2,149 peopleC-reactive protein